Metaraminol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Doc James (talk | contribs) at 01:39, 2 November 2014 (Reverted edits by Luklear (talk) to last version by 82.26.215.237). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Metaraminol
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • AU: C
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailabilityn/a
Protein binding~45%
MetabolismHepatic
Identifiers
  • (1R,2S)-3-[-2-amino-1-hydroxy-propyl]phenol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H13NO2
Molar mass167.205 g/mol g·mol−1
3D model (JSmol)
  • O[C@H](c1cc(O)ccc1)[C@@H](N)C
  • InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1 checkY
  • Key:WXFIGDLSSYIKKV-RCOVLWMOSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Metaraminol (INN; trade names Aramine, Metaramin, and Pressonex), also known as metaradrine, a stereoisomer of meta-hydroxynorephedrine (3,β-dihydroxyamphetamine), is a potent sympathomimetic amine used in the prevention and treatment of hypotension, particularly as a complication of anesthesia. It is an α1-adrenergic receptor agonist with some β effect.

Metaraminol is also used in the treatment of priapism. Although not approved for this use, it appears to be effective.[1][2][3]

Synthesis

Metaraminol, L-1-(3-hydroxyphenyl)-2-aminopropan-1-ol, is synthesized in two ways. The first way is synthetic, and it is from 3-hydroxypropiophenone. The hydroxyl group is protected by alkylation with benzyl chloride, giving 3-benzyloxypropiophenone. Upon reaction with butyl nitrite, it undergoes nitrosation into the isonitrosoketone, which by reduction using hydrogen over Raney nickel turns into 1-(3-benzyloxyphenyl)-2-aminopropan-1-ol, the protecting benzyl group is removed by reduction using hydrogen over palladium catalyst, to give racemic metaraminol. The desired L-isomer is isolated with the help of (+)-tartaric acid.

Metaraminol synthesis: G. Erhart, L. Stein, DE 555404  (1930). E. W. Zeh, U.S. patent 1,951,229 (1934).

The second way is semisynthetic, consisting of fermentation of D-glucose in the presence of 3-acetoxybenzaldehyde, which forms (–)-1-hydroxy-1-(3-hydroxyphenyl)-acetone, the carbonyl group of which is reduced by hydrogen over a palladium catalyst in the presence of ammonia, giving metaraminol.

Metaraminol synthesis 2: Bockmuhl Max, Ehrhart Gustav, Stein Leonhard DE 571229  (1930). U.S. patent 1,948,162 (1934). W. H. Hartung, U.S. patent 1,995,709 (1935). IG Farben, GB 396951  (1932).

See also

References

  1. ^ McDonald M, Santucci R (2004). "Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol". Int Braz J Urol. 30 (2): 121–2. doi:10.1590/S1677-55382004000200007. PMID 15703094.
  2. ^ Koga S, Shiraishi K, Saito Y (1990). "Post-traumatic priapism treated with metaraminol bitartrate: case report". J Trauma. 30 (12): 1591–3. doi:10.1097/00005373-199012000-00029. PMID 2258979.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Block T, Sturm W, Ernst G, Staehler G, Schmiedt E (1988). "[Metaraminol in therapy of various forms of priapism]". Urologe A. 27 (4): 225–9. PMID 3140463.{{cite journal}}: CS1 maint: multiple names: authors list (link)